In prostate cancer, BRCA1/2 mutations represent around 13% of the of DDR genes alterations in tumor samples and 51% of all germline variants found in individuals affected by prostate cancer, with BRCA2 harboring the majority of variants [46]. The gene discussed is BRCA2; the disease is prostate carcinoma.